According to Bloomberg Ratings, the nine analysts currently monitoring Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have given the company an average recommendation of “Hold,” which implies that investors should maintain their current positions in the company’s stock. Three research experts recommend purchasing the stock, while five analysts think investors should maintain their current holdings of the security. Most analysts who have updated their company coverage in the past year have set their price objective for the next 12 months at an average of $10.25. This is the price goal that the majority of analysts have established. Several research analysts have recently supplied their input on the KPTI stock that has been available recently. In research that was made public on Friday, August 5th, Barclays dropped their price objective on Karyopharm Therapeutics shares from $14.00 to $8.00 and gave the company an “overweight” rating. In a research note released on Friday, August 5th, Wainwright dropped their price goal on Karyopharm Therapeutics shares from $21.00 to $18.00 in a research note.
Despite this, they maintained their “buy” rating on the company. Finally, but certainly not least, in a research note released on Friday, August 5th, Robert W. Baird decreased their price objective on Karyopharm Therapeutics shares from $17.00 to $14.00 while maintaining an “outperform” rating on the company. As was reported in other news about the firm, Director Deepika Pakianathan sold 325,977 shares of Karyopharm Therapeutics stock on Wednesday, June 8th. The sale of the shares brought in a total of $2,118,850.50 in money, with an average price of $6.50 per share received for each share. As a direct result of the acquisition, the director has direct ownership of 18,731 shares. Based on the current market value, these shares are projected to be worth around $121,751.50. An SEC file has been submitted; it is possible to receive a copy of the transaction’s announcement from this website, where the filing can also be found. The insiders of the company made a total profit of $2,174,368 from the sale of 336,407 shares of company stock in the prior three months. Private ownership is 10.24% of the company’s total shares by employees and other company insiders. As a consequence of recent occurrences, institutional investors have shifted the proportion of their holdings that are held in the company.
IndexIQ Advisors LLC made a new investment of about $394,000.00 in Karyopharm Therapeutics during the first three months of 2018, acquiring a new ownership interest in the company. During the fourth quarter, Northern Trust Corporation’s holdings increased by 1.1%, and Karyopharm Therapeutics was one of the companies that benefited from this gain. Northern Trust Corp now has a total of 775,551 shares of the company’s stock, with a value of $4,986,000. This resulted from the acquisition of 8,491 additional shares during the preceding quarter. During the last three months of 2018, The Baird Financial Group Inc. increased the proportion of its holdings that were comprised of Karyopharm Therapeutics by 12.1%. Baird Financial Group Inc. now has 19,817 shares of the company’s stock, which are worth a total of $127,000 after the firm acquired an additional 2,137 shares during the past quarter. During the first three months of 2018, Running Point Capital Advisors LLC made a new investment in Karyopharm Therapeutics.
The potential earnings for this brand-new role were close to $74,000. The Teacher Retirement System of Texas made a new investment at the end of the year by purchasing shares of Karyopharm Therapeutics for a total value of roughly $84,000 during the fourth quarter of the year. This was done during the final quarter of the year. At the moment, institutional investors own 67.75% of the whole company’s stock. When trading started on Tuesday, a single share of KPTI was valued at $5.14 per unit. Karyopharm Therapeutics had an all-time low of $4.00 last year, while the business reached an all-time high of $14.73 during the same period. According to recent financial statements, the company has a market value of $410.21 million, a price-to-earnings ratio of -3.72, and a beta value of 0.02. The simple moving average of the company’s stock price over the past fifty days is $4.93, and the simple moving average for the last 200 days is $6.34. Karyopharm Therapeutics (NASDAQ: KPTI) released a report on August 4th detailing the company’s most recent quarterly profitability.
Earnings per share for the quarter reported by the firm came in at $0.62, which is $0.01 less than the consensus estimate of $0.63 from analysts. The revenue for the quarter was $39.68 million, which was much more than the consensus estimate of $36.38 million provided for the period. The projections of market analysts indicate that Karyopharm Therapeutics will finish the current fiscal year with a loss of -2.07 cents per share in their tally of profits and losses. Karyopharm Therapeutics Inc. is a pharmaceutical firm that has achieved the point of commercialization and finds, develops, and sells anti-nuclear export medications for the treatment of various disorders, including cancer. The company has also reached this phase of commercialization. The new selective nuclear export inhibitor (SINE) pharmaceuticals are researched, manufactured, and marketed by the company. These drugs do what they are supposed to do by attaching to the nuclear export protein XPO1 and stopping it from doing its job.